Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.

Phillips W, Piller LB, Williamson JD, Whittle J, Jafri SZ, Ford CE, Einhorn PT, Oparil S, Furberg CD, Grimm RH Jr, Alderman MH, Davis BR, Probstfield JL; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2013 Nov;15(11):825-32. doi: 10.1111/jch.12180. Epub 2013 Aug 7.

2.

Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Oliveto A, Mancino M, Sanders N, Cargile C, Benjamin Guise J, Bickel W, Brooks Gentry W.

Eur J Pharmacol. 2013 Sep 5;715(1-3):424-35. doi: 10.1016/j.ejphar.2013.03.007. Epub 2013 Mar 21.

3.

Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.

Karnes JH, Cooper-DeHoff RM.

Expert Rev Cardiovasc Ther. 2009 Jun;7(6):689-702. doi: 10.1586/erc.09.31. Review.

4.

Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall.

Campbell F, Dickinson HO, Cook JV, Beyer FR, Eccles M, Mason JM.

BMC Health Serv Res. 2006 Apr 5;6:47.

5.

Diuretics: again the first step in the treatment of most patients with hypertension.

Fuchs FD.

Curr Control Trials Cardiovasc Med. 2001;2(5):244-248.

6.

Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?

Wright JM, Lee CH, Chambers GK.

CMAJ. 1999 Jul 13;161(1):25-32. Review. No abstract available.

7.

Calcium channel blockers: is the jury still out?

Wright JM.

BMJ. 1998 Dec 5;317(7172):1591-2. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk